On the Alert for Cytokine Storm: Immunopathology in COVID-19

Lauren A Henderson, Scott W Canna, Grant S Schulert, Stefano Volpi, Pui Y Lee, Kate F Kernan, Roberto Caricchio, Shawn Mahmud, Melissa M Hazen, Olha Halyabar, Kacie J Hoyt, Joseph Han, Alexei A Grom, Marco Gattorno, Angelo Ravelli, Fabrizio De Benedetti, Edward M Behrens, Randy Q Cron, Peter A Nigrovic, Lauren A Henderson, Scott W Canna, Grant S Schulert, Stefano Volpi, Pui Y Lee, Kate F Kernan, Roberto Caricchio, Shawn Mahmud, Melissa M Hazen, Olha Halyabar, Kacie J Hoyt, Joseph Han, Alexei A Grom, Marco Gattorno, Angelo Ravelli, Fabrizio De Benedetti, Edward M Behrens, Randy Q Cron, Peter A Nigrovic

Abstract

Poor outcomes in COVID-19 correlate with clinical and laboratory features of cytokine storm syndrome. Broad screening for cytokine storm and early, targeted antiinflammatory therapy may prevent immunopathology and could help conserve limited health care resources. While studies are ongoing, extrapolating from clinical experience in cytokine storm syndromes may benefit the multidisciplinary teams caring for patients with severe COVID-19.

© 2020, American College of Rheumatology.

Figures

Figure 1
Figure 1
The family of conditions characterized by cytokine storm. Malig. = malignancy; Assoc. = associations; SJIA = systemic juvenile idiopathic arthritis; MAS = macrophage activation syndrome; CRS = cytokine release syndrome; ARDS = acute respiratory distress syndrome; EBV = Epstein‐Barr virus; HLH = hemophagocytic lymphohistiocytosis.

References

    1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID‐19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.
    1. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020. E‐pub ahead of print.
    1. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunologic features in severe and moderate coronavirus disease 2019. J Clin Invest 2020;130:2620–9.
    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
    1. Eloseily EM, Weiser P, Crayne CB, Haines H, Mannion ML, Stoll ML, et al. Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. Arthritis Rheumatol 2020;72:326–34.
    1. Weiss ES, Girard‐Guyonvarc'h C, Holzinger D, de Jesus AA, Tariq Z, Picarsic J, et al. Interleukin‐18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. Blood 2018;131:1442–55.
    1. Schulert GS, Zhang M, Fall N, Husami A, Kissell D, Hanosh A, et al. Whole‐exome sequencing reveals mutations in genes linked to hemophagocytic lymphohistiocytosis and macrophage activation syndrome in fatal cases of H1N1 influenza. J Infect Dis 2016;213:1180–8.
    1. Kumar B, Aleem S, Saleh H, Petts J, Ballas ZK. A personalized diagnostic and treatment approach for macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in adults. J Clin Immunol 2017;37:638–43.
    1. Carcillo JA, Simon DW, Podd BS. How we manage hyperferritinemic sepsis‐related multiple organ dysfunction syndrome/macrophage activation syndrome/secondary hemophagocytic lymphohistiocytosis histiocytosis. Pediatr Crit Care Med 2015;16:598–600.
    1. Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et al. Interleukin‐1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med 2016;44:275–81.
    1. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371:1507–17.
    1. Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, Leung CY, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet 2003;361:1773–8.
    1. Huang KJ, Su IJ, Theron M, Wu YC, Lai SK, Liu CC, et al. An interferon‐γ‐related cytokine storm in SARS patients. J Med Virol 2005;75:185–94.
    1. Centers for Disease Control and Prevention . Coronavirus disease (2019). Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID‐19). March 2020. URL: .
    1. Lansbury LE, Rodrigo C, Leonardi‐Bee J, Nguyen‐Van‐Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza: an updated Cochrane systematic review and meta‐analysis. Crit Care Med 2020;48:e98–106.
    1. Lee N, Allen Chan KC, Hui DS, Ng EK, Wu A, Chiu RW, et al. Effects of early corticosteroid treatment on plasma SARS‐associated coronavirus RNA concentrations in adult patients. J Clin Virol 2004;31:304–9.
    1. Halyabar O, Chang MH, Schoettler ML, Schwartz MA, Baris EH, Benson LA, et al. Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome. Pediatr Rheumatol Online J 2019;17:7.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner